Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CTR20261894 DYX116 Diabetes Mellitus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
CTR20261894 clinical trial report covering DYX116, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07589842 Aldesleukin(Assistance Publique Hopitaux De Paris) Autism Spectrum Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07589842 clinical trial report covering Aldesleukin(Assistance Publique Hopitaux De Paris), Phase 2, endpoints, sponsor, geography, readout timing and deve
Latest Hotspot
8 min read
ChiCTR2600124761 Tislelizumab Sinonasal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600124761 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600124759 Zeprumetostat Non-Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600124759 clinical trial report covering Zeprumetostat, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600124827 AAPB Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600124827 clinical trial report covering AAPB, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07591831 Irinotecan Hydrochloride Lioposome (Hunan Jingfeng) Platinum-Resistant Primary Peritoneal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07591831 clinical trial report covering Irinotecan Hydrochloride Lioposome (Hunan Jingfeng), Phase 2, endpoints, sponsor, geography, readout timing and dev
Latest Hotspot
8 min read
NCT07593040 Belzutifan Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07593040 clinical trial report covering Belzutifan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07592858 Colesevelam Hydrochloride Van Der Woude Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07592858 clinical trial report covering Colesevelam Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07592767 Resveratrol Parkinson Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07592767 clinical trial report covering Resveratrol, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07593079 Flotufolastat F-18 Recurrent Prostate Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07593079 clinical trial report covering Flotufolastat F-18, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07594015 Pembrolizumab Recurrent Endometrial Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07594015 clinical trial report covering Pembrolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261912 AL-001 (Anlong) Diabetic Retinopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
CTR20261912 clinical trial report covering AL-001 (Anlong), Phase 2, endpoints, sponsor, geography, readout timing and development white space.